Navigation Links
David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer
Date:9/4/2013

REDWOOD CITY, Calif., Sept. 4, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that David H. Chung has joined the company as chief commercial officer effective September 2, 2013.  Mr. Chung brings over 20 years of hospital-focused, global medical device and pharmaceutical sales and marketing experience, most recently as chief commercial officer at Conceptus, Inc., which was recently acquired by Bayer.  Mr. Chung will provide strategic input to AcelRx and will be responsible for establishing, developing and leading the Company's commercial operations.

"David has extensive sales and marketing experience in the hospital-based products market, and a proven track record of commercial success," said Richard King, AcelRx's president and CEO.  "We are extremely excited to welcome David to the AcelRx executive team, and we look forward to David's leadership in establishing and building a first class commercial organization to support, if approved, launch of Zalviso™ for management of moderate to severe acute pain in the hospital setting."

While at Conceptus, Mr. Chung oversaw the strategic and day-to-day leadership of a global sales and marketing organization that consisted of 144 people.  Prior to Conceptus, Mr. Chung served as president and CEO of Mitralis, an early stage transcatheter mitral valve repair company.  Prior to Mitralis, Mr. Chung held the position of global vice president, commercial operations, Heart Valve Therapy at Edwards Lifesciences/Baxter Healthcare, the culmination of 15 years at the company in various commercial roles of increasing responsibility.  Prior to Baxter, Mr. Chung began his career at Pfizer in a sales capacity in both the medical device and pharmaceutical sales arenas.  Mr. Chung earned a B.S. in general engineering from the United States Military Academy, West Point, N.Y.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, Zalviso™, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps.  AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and AcelRx anticipates submitting a New Drug Application (NDA) with the FDA in the third quarter of 2013.  AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from the U.S. Army Medical Research and Materiel Command.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the process and timing of anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, the potential submission of an NDA for Zalviso and the timing thereof, therapeutic and commercial potential of Zalviso and the anticipated timing and therapeutic and commercial potential of other AcelRx product candidates.  These forward-looking statements are based on AcelRx's current expectations and inherently involve significant risks and uncertainties.  AcelRx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx's product development activities and clinical trials; any delays or inability to obtain, regulatory approval of its product candidates; its ability to obtain adequate clinical supplies of the drug and device components of its product candidates; its ability to attract funding partners or collaborators with development, regulatory and commercialization expertise; its ability to obtain sufficient financing to complete development and registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; the accuracy of AcelRx's estimates regarding expenses, capital requirements and needs for financing; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx's U.S. Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the three months ended June 30, 2013, filed August 12, 2013.  AcelRx undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO )


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Law Offices of John David Hart: What Went Wrong with the Stryker ShapeMatch Cutting Guides?
2. PDL BioPharma Appoints David Montez as Controller and Chief Accounting Officer
3. Protagonist Therapeutics Names David Liu Chief Scientific Officer
4. Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg
5. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
6. Dr. David Altamira Announces New Non-Surgical Procedures
7. Dr. David Altamira Offering Enhanced Breast Implant Houston Consultations
8. MetaStat Appoints David Epstein, Ph.D. as Advisor to Lead Drug Discovery
9. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
10. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
11. Dynamic Healthcare Services Announces David Erb as Director of Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... Directors has approved the payment of a quarterly cash dividend ... The cash dividend of $0.24 per ... to stockholders of record as of the close of business ... to approval of the Board of Directors and may be ...
(Date:8/4/2017)... 3, 2017  Agragen, LLC, a ... the biopharmaceutical, nutraceutical, and aquacultural feed sectors, announces ... lead drug candidates, AGR131.  This drug is designed ... the blood of patients suffering from inflammatory conditions ... disease. Biological ...
(Date:8/2/2017)... -- CaryRx, a next-generation full-service pharmacy, has announced the launch ... the Washington D.C. metropolitan area. CaryRx ... of medications through the convenience of its patient-friendly mobile app. ... one hour to any location in D.C. ... service to Washington D.C. ," says Areo ...
Breaking Medicine Technology:
(Date:8/18/2017)... WV (PRWEB) , ... August 18, 2017 , ... ... financial consulting services and asset protection assistance to communities in North-Central West Virginia, ... provide critical services to at-risk boys in the area. , The Chestnut Mountain ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an Indiana-based ... campaigning in support of Campagna Academy in a charity drive to provide for at-risk ... Town of Indiana,” Campagna Academy is a nonprofit organization that has offered critical programs ...
(Date:8/18/2017)... ... 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the memo ... Generation Mindful. To help change the mindset of parents and educators from punitive to ... the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in ...
(Date:8/18/2017)... ... , ... Alcovit, a lime-flavored beverage that rids the body of toxins linked ... now available through Jet.com. , After 25 years of development, the company released ... to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun with ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Our Mountains to Climb: A Journey ... couple that grew stronger together through the faith they shared to overcome struggles in ... the creation of published author, Barbara J. Corcoran, a retired teacher and happily married ...
Breaking Medicine News(10 mins):